Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roivant Sciences Ltd ROIV

Healthcare Biotechnology
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal... see more

Recent & Breaking News (NDAQ:ROIV)

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

GlobeNewswire March 15, 2023

Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

GlobeNewswire March 14, 2023

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

GlobeNewswire March 14, 2023

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

GlobeNewswire March 7, 2023

Roivant Sciences Announces Change to its Board of Directors

GlobeNewswire February 21, 2023

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

GlobeNewswire February 13, 2023

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

GlobeNewswire February 2, 2023

Roivant Sciences Announces Proposed Public Offering of Common Shares

GlobeNewswire February 1, 2023

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

GlobeNewswire January 30, 2023

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations

GlobeNewswire January 4, 2023

Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant

PR Newswire December 7, 2022

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

GlobeNewswire December 1, 2022

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

GlobeNewswire November 14, 2022

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

GlobeNewswire November 10, 2022

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

GlobeNewswire November 8, 2022

Roivant Sciences Announces Proposed Public Equity Offering

GlobeNewswire November 7, 2022

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

GlobeNewswire October 18, 2022

Roivant to Participate in September Investor Events

GlobeNewswire August 30, 2022

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

GlobeNewswire August 15, 2022

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

GlobeNewswire August 3, 2022